Loading clinical trials...
Loading clinical trials...
Efficacy, Safety, and Tolerability of a GLP-1/GCG Dual Receptor Agonist in Type 2 Diabetes With Early Dementia: A Multicenter, Randomized, Parallel-group, Double-blind, Placebo-controlled Trial
Conditions
Interventions
Mazdutide
Placebo
Locations
8
China
Department of Endocrinology, Xiangya Hospital of Central South University
Changsha, Hunan, China
Department of Endocrinology, Changzhou No.2 People's Hospital
Changzhou, Jiangsu, China
Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University
Nanjing, Jiangsu, China
Department of Endocrinology, Endocrine and Metabolic Disease Medical Center,Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
Nanjing, Jiangsu, China
Department of Endocrinology, Jiangsu Province Hospital of Traditional Chinese Medicine
Nanjing, Jiangsu, China
The Second Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, China
Start Date
September 27, 2025
Primary Completion Date
August 1, 2029
Completion Date
August 1, 2029
Last Updated
March 5, 2026
NCT07232537
NCT07101380
NCT06815081
NCT06121544
NCT06003153
NCT06278207
Lead Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions